Zosano Pharma Announces Agreement To Collaborate With Mitsubishi Tanabe Pharma Corporation

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, today announced that it has entered into a feasibility study agreement with Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company that develops and commercializes innovative therapies for patients addressing unmet medical needs, centered on its priority disease areas — autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines. “Our agreement with Mitsubishi Tanabe Pharma Corporation allows us to combine our proprietary transdermal microneedle drug delivery platform with Mitsubishi Tanabe Pharma Corporation’s drug development candidate,” said Steven Lo, President and CEO of Zosano. “We expect through this partnership, to demonstrate the broad applicability of our platform for making a difference in the lives of patients when combined with pharmaceutical products that address significant unmet medical needs.” Under the agreement, Zosano will evaluate the feasibility of formulating a pharmaceutical agent being developed by Mitsubishi Tanabe Pharma Corporation for administration in humans, with its proprietary microneedle patch system. Defined research and development activities will include both in vitro and in vivo phases. Mitsubishi Tanabe Pharma Corporation receives the right to exercise an option to negotiate an exclusive license to the relevant Zosano technologies in the defined field, which exercise will be dependent on the outcome of the studies. Financial terms and the identity of the Mitsubishi Tanabe Pharma Corporation molecule and development program are not disclosed.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!